GH Research (GHRS) Interest Income - Total (2022 - 2025)
GH Research (GHRS) posted quarterly Interest Income - Total of $3.4 million for Q4 2025, up 260.1% year-over-year from $939450.5 in Q4 2024, and down 76.69% quarter-over-quarter from $14.5 million in Q3 2025.
GH Research (GHRS) Interest Income - Total (2022 - 2025) Analysis & Trends
GH Research's Interest Income - Total history runs 4 years deep, the most recent figure standing at $3.4 million for Q4 2025.
- In Q4 2025, Interest Income - Total rose 260.1% year-over-year to $3.4 million; the TTM figure through Dec 2025 stood at $12.1 million (up 222.15% YoY), while the FY2025 annual figure was $12.1 million, up 222.15% from the prior year.
- Interest Income - Total for Q4 2025 stood at $3.4 million, down from $14.5 million in the prior quarter.
- The five-year high for Interest Income - Total was $14.5 million in Q3 2025, with the low at -$3.1 million in Q2 2025.
- The 4-year median for Interest Income - Total is -$2.4 million (2023), against an average of -$612076.9.
- The sharpest annual moves came in 2023 and 2025: Interest Income - Total sank 151.2% in 2023, then jumped 672.39% in 2025.
- GH Research's Interest Income - Total stood at -$1.2 million in 2022, then tumbled by 151.2% to -$2.9 million in 2023, then grew by 27.86% to -$2.1 million in 2024, then soared by 260.1% to $3.4 million in 2025.
- Business Quant data shows GHRS's Interest Income - Total at $3.4 million in Q4 2025, $14.5 million in Q3 2025, and -$3.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Total (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.38 Mn |
| Dec 31, 2025 | 3.38 Mn |
| Sep 30, 2025 | 14.51 Mn |
| Sep 30, 2025 | 14.51 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Mar 31, 2025 | -2.76 Mn |
| Mar 31, 2025 | -2.76 Mn |
| Dec 31, 2024 | -2.11 Mn |
| Dec 31, 2024 | -2.11 Mn |
| Sep 30, 2024 | -2.54 Mn |
| Sep 30, 2024 | -2.54 Mn |
| Jun 30, 2024 | -2.56 Mn |
| Jun 30, 2024 | -2.56 Mn |
| Mar 31, 2024 | -2.67 Mn |
| Mar 31, 2024 | -2.67 Mn |
| Dec 31, 2023 | -2.93 Mn |
| Dec 31, 2023 | -2.93 Mn |
| Sep 30, 2023 | -2.44 Mn |
| Sep 30, 2023 | -2.44 Mn |